Interferon Beta-1a for Multiple Sclerosis from Japan
Recombinant human interferon beta-1a injection for therapeutic management of relapsing multiple sclerosis. Under HTS 3002.90.52 as an immunological product involved in immune regulation. Biotechnologically produced for weekly subcutaneous use.
Duty Rate — Japan → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Refrigerated shipping mandatory; include expiry date validation
• Biotech COA required to prove recombinant vs plasma origin
• Check for orphan designation benefits in duty drawback programs